Physician profile
Glory Abraham
NPI 1194206490
$1,417.26
in general payments reported to CMS, 2019-2025
11 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $546 · 2023: $353 · 2024: $348 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $434.28 | 2022-2025 | Delstrigo, Pifeltro, Dificid |
| Gilead Sciences, INC. | $414.81 | 2022-2024 | |
| Viiv Healthcare Company | $282.49 | 2022-2025 | Apretude, Cabenuva, Dovato |
| Theratechnologies INC. | $63.40 | 2022 | |
| Janssen Biotech, INC. | $59.79 | 2022-2023 | Symtuza |
| Abbott Laboratories | $48.16 | 2024-2025 | Freestyle Libre 3 |
| Emd Serono, INC. | $42.95 | 2022 | |
| Napo Pharmaceuticals INC | $24.53 | 2025 | Mytesi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.22 | 2023 | |
| Vbi Vaccine (Delaware) INC. | $16.83 | 2023 | Prehevbrio |
| Abbvie INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glory Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.